Cantor Fitzgerald has reiterated its Overweight rating and $93.00 price target for Ventas (NYSE:VTR) after the healthcare REIT’s strong fourth-quarter 2025 results and positive 2026 outlook. The firm highlighted 15% same-store NOI growth in the Senior Housing Operating Portfolio (SHOP) segment and sees potential for raised forecasts. Despite a positive analyst consensus and consistent dividends, InvestingPro’s Fair Value assessment suggests the stock may be overvalued.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cantor Fitzgerald reiterates Overweight rating on Ventas stock at $93
Cantor Fitzgerald has reiterated its Overweight rating and $93.00 price target for Ventas (NYSE:VTR) after the healthcare REIT’s strong fourth-quarter 2025 results and positive 2026 outlook. The firm highlighted 15% same-store NOI growth in the Senior Housing Operating Portfolio (SHOP) segment and sees potential for raised forecasts. Despite a positive analyst consensus and consistent dividends, InvestingPro’s Fair Value assessment suggests the stock may be overvalued.